Free Trial
NASDAQ:BIAF

bioAffinity Technologies Q1 2023 Earnings Report

bioAffinity Technologies logo
$0.28 -0.01 (-4.83%)
Closing price 07/3/2025 03:55 PM Eastern
Extended Trading
$0.28 +0.00 (+0.36%)
As of 07/3/2025 04:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

bioAffinity Technologies EPS Results

Actual EPS
-$0.18
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

bioAffinity Technologies Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

bioAffinity Technologies Announcement Details

Quarter
Q1 2023
Time
N/A
Conference Call Date
Monday, May 15, 2023
Conference Call Time
7:00AM ET

Upcoming Earnings

bioAffinity Technologies' Q2 2025 earnings is scheduled for Wednesday, August 13, 2025, with a conference call scheduled on Thursday, August 14, 2025 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

bioAffinity Technologies Earnings Headlines

DeFi Coin on Verge of Breakout!
What my billionaire friends are doing before Bitcoin vanishes Bitcoin is literally being drained from exchanges at a rate I've never witnessed in my 8+ years in crypto. I've rushed out a special guide revealing exactly what to do before this supply crisis fully hits – and for a limited time, it's yours for just $3.
See More bioAffinity Technologies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like bioAffinity Technologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on bioAffinity Technologies and other key companies, straight to your email.

About bioAffinity Technologies

bioAffinity Technologies (NASDAQ:BIAF), a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level. The company was incorporated in 2014 and is based in San Antonio, Texas.

View bioAffinity Technologies Profile

More Earnings Resources from MarketBeat